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Myxomatosis in European rabbits is a severely debilitating disease characterized by profound systemic cellular immuno-
suppression and a high rate of mortality. The causative agent, myxoma virus, is a member of the poxvirus family and
prototype of the Leporipoxvirus genus. As a major step toward defining the genetic strategies by which the virus circumvents
host antiviral responses, the genomic DNA sequence of myxoma virus, strain Lausanne, was determined. A total of 171 open
reading frames were assigned to cover the 161.8-kb genome, including two copies each of the 12 genes that map within the
11.5-kb terminal inverted repeats. Database searches revealed a central core of approximately 120 kb that encodes more
than 100 genes that exhibit close relationships to the conserved genes of members of other poxvirus genera. Open reading
frames with predicted signal sequences, localization motifs, or homology to known proteins with immunomodulatory or
host-range functions were examined more extensively for predicted features such as hydrophobic regions, nucleic acid
binding domains, ankyrin repeats, serpin signatures, lectin domains. and structural cysteine spacings. As a result, several
novel, potentially immunomodulatory proteins have been identified, including a family with multiple ankyrin-repeat domains,
an OX-2 like member of the neural cell adhesion molecule family, a third myxoma serpin, a putative chemokine receptor
fragment, two natural killer receptor-like species, and a variety of species with domains closely related to diverse host
immune regulatory proteins. Coupled with the genomic sequencing of the related leporipoxvirus Shope fibroma virus, this
work affirms the existence of a conserved complement of poxvirus-specific core genes and expands the growing repertoire
of virus genes that confer the unique capacity of each poxvirus family member to counter the immune responses of the
infected host. © 1999 Academic Press
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Myxoma virus is a member of the Leporipoxvirus ge-
us, Chordopoxvirinae subfamily, and Poxviridae family
Fenner, 1979). Other members of the Leporipoxvirus
enus include Shope fibroma virus (SFV), hare fibroma
irus, and squirrel fibroma virus. Like all members of the
oxvirus family, myxoma virus possesses a large, linear
ouble-stranded DNA genome with terminal inverted re-
eats (TIRs) and covalently closed hairpin loops at each
nd (Moss, 1996). The genome is contained within a
haracteristic brick-shaped virion, and viral replication
ccurs solely in the cytoplasm of infected cells. Myxoma
irus, like other members of the poxvirus family, has the
bility to successfully and strategically circumvent or
isrupt critical facets of the host antiviral responses
McFadden et al., 1995; Nash et al., 1999).
Myxoma virus causes a mild, benign infection in its
volutionary host, the North American brush rabbit (Syl-
ilagus californicus) or the South American tapeti (Syl-
1 The first two authors contributed equally to this work and should
oth be considered as first authors.
2 To whom reprint requests should be addressed at 1400 Western
voad, N6G 2V4. Fax: (519) 663-3847. E-mail: mcfadden@rri.on.ca.
042-6822/99 $30.00
opyright © 1999 by Academic Press
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298ilagus brasiliensis), but it causes a rapid systemic and
ethal infection known as myxomatosis in European rab-
its (Oryctolagus cuniculus) with mortality rates up to
irtually 100% (Fenner, 1983). Myxomatosis is an exten-
ively characterized veterinary disease that provides a
ell-defined in vivo model for the study of virus-encoded
irulence factors, including those involved in immuno-
odulation. The symptoms and mortality rates associ-
ted with myxomatosis are believed to be the result of
ultiorgan dysfunction coupled with uncontrolled sec-
ndary gram-negative bacterial infections due to a pro-
ressive impairment of the host cellular immune re-
ponse. Myxomatosis is transmitted via arthropod vec-
ors, most notably the mosquito (Fenner and Ratcliffe,
965). In the early 1950s, myxoma virus was released in
ustralia in an effort to reduce the problematic feral
uropean rabbit populations. This biological approach to
est control proved to be ineffective due to the combi-
ation of increased host resistance in the surviving rab-
it populations and genetic attenuation of field virus
trains (Fenner and Ratcliffe, 1965; Kerr and Best, 1998).
The well-characterized pathogenic relationship be-
ween myxoma virus and the European rabbit host pro-
ides an ideal model system in which to analyze the
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299MYXOMA VIRUS GENOMIC SEQUENCEbility of a large DNA virus to modulate the antiviral
esponses of the host immune system. To better under-
tand this phenomenon, we undertook the sequencing of
he entire DNA genome of myxoma virus (strain Lau-
anne) to enable a systematic survey of the functions of
ll the putative immunomodulatory genes. This strategy
as been used successfully by a number of other groups
o identify novel immunomodulatory virus genes. For ex-
mple, the complete genomic sequence analyses of vac-
inia (VAC), variola (VAR), and Molluscum contagiosum
evealed a plethora of potential immunomodulatory
enes (Antoine et al., 1998; Goebel et al., 1990; Massung
t al., 1994; Senkevich et al., 1997; Shchelkunov et al.,
995). The first molecular characterization of the myxoma
irus genome was carried out by Russell and Robbins
1989) in which restriction enzyme maps for three differ-
nt strains of myxoma virus were determined. Since
hen, however, only fragmentary sequencing studies
ave been carried out (see Jackson and Hall, 1998; Nash
t al., 1999 for references). We present here a compre-
ensive analysis of the myxoma virus genomic se-
uence, focusing primarily on prospective novel immu-
omodulatory genes and their possible functions. In the
ompanion paper (Willer et al., 1999), the sequence of
he related leporipoxvirus, SFV, is presented, with dis-
ussion centered primarily on genes involved in replica-
ion and repair.
RESULTS AND DISCUSSION
eneral features of the myxoma genome
The myxoma virus genome (strain Lausanne) was de-
ermined to be 161774 nucleotides in length and has an
/T content of 56.4%, which is less A/T rich than the
nown orthopoxvirus genomes (Goebel et al., 1990). The
yxoma genome was assembled from approximately
000 individual nucleotide sequencing reactions repre-
enting both strands with an overall 5.6-fold redundancy.
he myxoma virus TIRs are 11.5 kb in length, which is
horter than the 12.4-kb TIRs of SFV (Cabirac et al., 1985;
pton et al., 1987). The boundary between the myxoma
IRs and unique central core sequences was found to
xist between the M008.1L/R and the M009L/M156R
enes (Fig. 1). Therefore, M009L is not a part of the TIR,
s is the case of S009L in SFV (Willer et al., 1999). Seven
olymorphic loci were found to exist at nucleotides: 209
T/A), 40404 (C/T), 65028 (C/T), 111824 (A/C), 112369
A/G), 112588 (A/G), and 161566 (A/T). Of these polymor-
hic nucleotides, three (at positions 209, 40404, and
61566) are within intergenic regions, and a fourth (at
5028) is within M068R but maintains the amino acid (aa)
eucine at that position. The remaining three polymor-
hisms are all within a single open reading frame (ORF),
114R (the RNA polymerase 132-kDa subunit). The first
olymorphic site results in a lysine or threonine at aa
osition 858, the second polymorphic site results in ei- ther an arginine or glycine residue at position 1040, and
he final polymorphic site results in a threonine or ala-
ine at aa position 1113.
Our deduced genomic length falls slightly short of the
redicted 163.6 6 0.2 kb length based on restriction
nzyme mapping of myxoma virus, strain Lausanne (Rus-
ell and Robbins, 1989). We compared the fragments
redicted from the deduced sequence with those ob-
erved in the publication of Russell and Robbins, and the
estriction enzyme fragment profiles were consistent
ith the published map (not shown).
yxoma virus ORF arrangements
With all available reading frames, the number of pos-
ible myxoma virus ORFs encoding proteins of a mini-
um length of 50 aa was calculated to be 425. We based
ur gene assignment strategy on the fact that poxviruses
end to have a compact and efficiently organized ge-
ome, with the genes aligned closely one after another
r slightly overlapping. Based on homologies to known
oxvirus genes (as established by BLASTp scores) and
omparison with the ORFs predicted in the recently se-
uenced SFV genome (Willer et al., 1999), we have as-
igned 159 myxoma ORFs predicted to be colinear ex-
ressed genes. One gene (M037L) encoding only a
2-aa putative protein was included in the list of as-
igned genes. Thus a total of 159 assigned genes span
he myxoma virus genome, of which 12 are present in
iploid in the TIRs, giving a total of 171 genes from the
ull-length genome.
Our gene nomenclature was based loosely on those
sed for Melanoplus sanguinipes and M. contagiosum
Afonso et al., 1999; Senkevich et al., 1997) and was
evised to correspond closely with that of the SFV ge-
ome (Willer et al., 1999). Beginning at the left-most end
f the genome, the TIR genes were designated in a
ashion consistent with the names used in previous ar-
icles and then continued in increasing numerical order
rom the left-most genes. Thus M-T1 was renamed
001R/L, M-T2 became M002R/L, and so on until M156R
with the exclusion of M145). Four notable exceptions to
he numeric scheme are M000.5 R/L, which is an ORF
ound only in the termini of the myxoma genome; M-T3A
nd M-T3C, which became M003.1 R/L and M003.2 R/L;
ERP-1, which became M008.1 R/L; and M153.1R, which
s uniquely found in myxoma. All ORFs were assigned
he designation R (right) or L (left) to represent the direc-
ion of transcription.
All of the assigned myxoma ORFs are represented in a
inear fashion in Fig. 1. A color scheme is provided to
unctionally assign the ORFs with regard to their pre-
icted functions. The most obvious feature of the myx-
ma genome is the presence of genes with putative,
onserved housekeeping (represented in red) or struc-ural functions (yellow) in the central portion of the ge-
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301MYXOMA VIRUS GENOMIC SEQUENCEome extending from M012L to M142R, whereas genes
ontaining motifs that imply a role in immunomodulation
r host range (green) tend to be closer to the termini.
enes with undefined functions are shown in black.
hus the central 120 kb of the myxoma genome repre-
ents most of the essential genetic information common
o all poxviruses, whereas the flanking 40 kb (approxi-
ately 15 kb at the left and 25 kb at the right) are
nriched for genes that are more demonstrably specific
or the Leporipoxvirus genus.
The map of the myxoma virus genome illustrates the
fficient use of coding capacity in poxviruses (Fig. 1).
here is little evidence of wasted space, and in contrast
o other poxviruses, there is no indication of noncoding
NA or significant stretches of repetitive DNA within the
IR, with the exception of nine tandem copies of a con-
erved nonamer/decamer between M002L/R and
003.1L/R. Although the TIR region of sequenced poxvi-
uses is variable in length and sequence, the regions
enerally encode a small number of genes and include
ignificant stretches of noncoding DNA. For example,
here is almost 6 kb of noncoding DNA at the termini of
accinia Ankara strain (Antoine et al., 1998), 3 kb in
ntomopoxvirus (M. sanguinipes) (Afonso et al., 1999), 3
b in M. contagiosum virus (Senkevich et al., 1997), and
kb in vaccinia Copenhagen (Johnson et al., 1993). In
ontrast, there are contiguous ORFs right up to the ter-
ini in myxoma.
All 159 myxoma ORFs are presented in Table 1. For
ach ORF, the nucleotide span within the myxoma ge-
ome and number of aa encoded are provided. Also
ndicated are the best protein matches in the public
omain database in terms of the best smallest sum
robability BLASTp score and, in certain cases, a second
elevant match in the database. As a reference for each
f the matches, SWISS-PROT or GENBANK accession
umbers are provided. Based on the relevant matches,
utative functions and/or predicted activities are given
or most of the ORFs. The degree of conservation of each
RF with its closest poxvirus gene homolog is indicated
s U (unique, defined as having less than 20% aa identity
ith a previously sequenced poxvirus gene outside the
eporipoxvirus genus), S (semiconserved, having identity
f 20–50%), or C (conserved, having identity of greater
han 50%). As commonly observed in other poxviral ge-
omes, the ORFs closest to the ends of the genome are
ranscribed preferentially toward the nearest terminus.
Poxvirus promoters have been divided into the early,
ntermediate, and late temporal categories. Strong early
nd late promoters have been defined by mutational
nalysis, as have intermediate promoters, which were
irst identified with poxvirus genes encoding late-tran-
cription factors (Baldick et al., 1992; Davison and Moss,
989, 1990). A comparison of the promoter sequences
rom M. contagiosum and vaccinia virus identified con-
ensus sequence patterns for each of the three promoter types (Senkevich et al., 1997). Strong early promoters are
haracterized by a 15-nucleotide A-rich tract, often with a
nucleotide in the middle. Transcription initiation takes
lace 15–20 nucleotides downstream of the promoter.
he transcriptional initiation sites for two myxoma early
enes M001L/R and M011L have been mapped (Graham
t al., 1992; Macaulay and McFadden, 1989), and both
ites show corresponding A-rich domains 10–20 nucle-
tides upstream of the transcription start sites. In the
ase of M011L, the A-rich domain lies approximately 100
p upstream of the ORF, indicating that the early promot-
rs are not necessarily adjacent to the ORFs. Late pro-
oters are defined by the transcription initiation site
AAAT sequence, which often forms part of the initiating
ethionine codon by being followed by a G. In strong
ate promoters, the TAAAT is preceded by a short spacer
f 4–10 nucleotides and then a T-rich tract of 5–15 nu-
leotides. Intermediate promoters have a TA3–6T tran-
criptional initiation site that is similar to the late promot-
rs but are preceded by an AAANAA motif about 12–15 nt
pstream of the TAAA. These promoter elements have
een conserved among the leporiviruses and orthopox-
iruses, and this is reflected by the identification of very
imilar consensus promoter sequences in SFV (Willer et
l., 1999). Using these promoter sequence signatures,
e manually inspected the regions upstream of each
RF in the myxoma virus genome and tentatively classi-
ied each of the promoter elements (Table 1).
An interesting feature of the myxoma genome organi-
ation revealed in Fig. 1 and Table 1 is that the basic
rder of centrally located genes in vaccinia virus, strain
openhagen (Johnson et al., 1993), is fairly well main-
ained in the core 120 kb of the myxoma virus genome. In
act, myxoma M012L–M140R are shown to have signifi-
ant homology to VAC F2L through A55R, with certain
oteworthy exceptions. No myxoma homologs are found
o VAC F5L, F6L, F11L, F14L, E11L, O2L, I4L, A25L, A26L,
31R, A36R, A39R–A49R, A53R, and A54L. In most of
hese cases, the function of the vaccinia virus homolog
issing from myxoma is unknown. In the case of the
issing VAC O2L, it appears that myxoma virus lacks this
lutaredoxin homolog (Ahn and Moss, 1992), although it
till possesses M048L, a homolog of the related VAC
lutaredoxin-2, G4L (Gvarkharia et al., 1996). The lack of
myxoma homolog of VAC I4L (the large subunit of
ibonucleotide reductase) and A48R (thymidylate kinase)
s also noteworthy because it implies that myxoma is
ikely more dependent than is vaccinia on the host cell
or nucleotide pools (Beaud, 1995). A more in-depth dis-
ussion of the functional relevance of these particular
eletions is found in the companion SFV publication
Willer et al., 1999).
Some of the other interesting genetic arrangements
nclude several insertions, duplications, rearrangements,
nd even a translocation of myxoma ORFs with respecto the order of their vaccinia counterparts. Three contig-
TABLE 1
Assigned Genes of Myxoma Virus
ORFsa
Nucleotide
positionb aac
Promoter
typed Relevant matches/homologse Putative function/structure f BLASTPg
Conservation
within
poxvirusesh
U S C
M000.5L/R 581–366
161194–161409
72 L U
M001L/R 1585–806
160190–160969
260 E VAC 35K major secreted protein
B29R/C23L (sp P21090)
Secreted chemokine binding
protein (Table 4) (M-T1, gi
2076755)
4.00e-36 S
M002L/R 2645–1668
159130–160107
326 E MPV TNF-R homolog (gi
2738073)/VAC B28R homolog
(gi 439102)
Soluble TNF receptor homolog
(M-T2, sp P29825) (Table 4)
6e-94/6e-93 S
M003.1L/R 3279–2827
158496–158948
151 E CAP T3A (gi 74384)/VAC B15R
(sp P21089)
3e-26/1e-10 S
M003.2L/R 3690–3352
158085–158423
113 ? CAP T3C (sp P18388) 6.00e-21 S
M004L/R 4636–3926
157139–157849
237 E CAP T4 (sp P18385)/VAC B9R
(sp P21005)
ER-localized apoptosis
regulator (Table 5) (M-T4, gi
2897907)
7e-34/6e-3 S
M004.1L/R 4912–4643
156863–157132
90 L? SPV C2L (sp P32230) 7.00e-15 U
M005L/R 6383–4935
155392–156840
483 E VAC B4R (sp P21001)/human
ankyrin (sp Q01485)
Ankyrin-like host range (Table
5) (M-T5, gi 1421732)
3e-14/2e-7 S
M006L/R 7948–6422
153827–155353
509 E SPV C4L (sp P32228)/VAC A55R
(sp P21073)
Kelch ring canal protein
homolog (M-T6 gi 4186093)
8e-70/1e-31 S
M007L/R 8776–7988
152999–153787
263 E SPV C6L (sp P32226)/VAC B8R
(sp P21004)
IFNg receptor homolog, a
chain (Table 4) (M-T7, gi
332308)
5e-22/5e-8 S
M008L/R 10374–8830
151401–152945
515 E SPV C4L (sp P32228)/VAC A55R
(sp P21073)
Kelch ring canal protein
homolog (M-T8, gi 332306)
5.3e-81/4e-32 S
M008.1L/R 11461–10355
150314–151420
369 L bovine plasminogen activator
inhibitor (sp P13909)
Secreted serpin (Table 4)
(SERP-1, sp P12393)
4.00e-45 U
M009L 13130–11604 509 E SPV C4L (sp P32228)/VAC A55R
(sp P21073)
Kelch ring canal protein
homolog (M-T9, sp P08073)
2e-67/4e-29 S
M010L 13643–13389 85 E TGFa (sp P01134)/VAC growth
factor (sp P20494)
EGF-like growth factor (Table
4) (MGF, sp P08072)
1e-3/7e-3 S
M011L 14125–13628 166 E SPV C10L (sp P32222) Integral membrane protein/
apoptosis regulator (Table
5) M11L (gi 279830)
7.00e-05 S
M012L 14584–14141 148 E VAC F2L (sp P21035) Deoxyuridine 59 triphosphate
nucleotidohydrolase
8.00e-41 C
M013L 14984–14607 126 E mouse IFN-inducible protein (gi
2465727)
IFN-inducible protein homolog 7.70e-02 U
M014L 16565–15015 517 E SPV C13L (sp P32206)/VAC F3L
(sp P21013)
Kelch-like protein 7e-98/3e-40 S
M015L 17586–16621 322 E VAC F4L (sp P20493) Ribonucleotide reductase,
small subunit
1.00e-45 C
M016L 17848–17618 77 ? SPV C15L (sp P32220) 2.00e-04 S
M017L 18088–17861 76 E U
M018L 18513–18316 66 E VAC F8L (sp P21017) Nonessential/cytoplasmic
protein
4.20e-02 S
M019L 19216–18572 215 L SPV C19L (sp P32207)/VAC F9L
(sp P21018)
3e-68/1e-57 C
M020L 20531–19197 445 L SPV C20L (sp P32216)/VAC
F10L (sp P21095)
Serine/threonine protein
kinase
0.00e00/1e-180 C
M021L 22526–20652 625 E VAC F12L (sp P21053) EEV maturation 1.00e-04 S
M022L 23673–22561 371 L VAC F13L (sp P20638) Palmitylated envelope
protein/EEV antigen
1.00e-17 C
M023R 23755–23937 61 L U
M024L 24285–23842 148 E VAC F15L (sp P21020) 4.00e-36 S
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ORFsa
Nucleotide
positionb aac
Promoter
typed Relevant matches/homologse Putative function/structure f BLASTPg
Conservation
within
poxvirusesh
U S C
M025L 24971–24345 209 E VAC F16L (sp P21021) 7.00e-30 S
M026R 25012–25317 102 L VAC F17R (sp P07397) DNA-binding phosphoprotein
(vp11-like)
1.00e-27 C
M027L 26729–25320 470 L VAC E1L (sp P21079) Poly(A) polymerase catalytic
subunit
0.00e00 C
M028L 28921–26729 731 L VAC E2L (sp P21080) 1.00e-62 S
M029L 29307–28963 115 E VAC E3L (sp P21081) IFN-resistance/PKR inhibitor/
host range (Table 5)
2.00e-20 S
M030L 30037–29372 222 E VAC E4L (sp P21082) RNA polymerase subunit
(rpo30)/VITF-1
4.00e-76 C
M031R 30138–31316 393 E VAC E5R (sp P21046) Virosome component 9.00e-15 S
M032R 31329–33023 565 L VAC E6R (sp P21047) 0.00e00 C
M033R 33029–33844 272 E VAC E8R sp P21049) 1.00e-05 C
M034L 36864–33847 1006 E VAC E9L (sp P20509) DNA polymerase 0.00e00 C
M035R 36898–37185 96 L, E? VAC E10R (sp P21050) 3.00e-38 C
M036L 39251–37212 680 E VAC O1L (sp P21093) Leucine zipper motif 1.00e-20 S
M037L 39385–39290 32 L FPV ortholog of VAC 03L and
MC043.1L (gi 3123527)
2.40e-01 U
M038L 40337–39399 313 L VAC I1L (sp P20498) Essential gene/DNA-binding/
virion morphogenesis
1.00e-17 C
M039L 40562–40341 74 L VAC I2L (sp P12922) 5.00e-11 S
M040L 41375–40566 270 I? VAC I3L (sp P20499) DNA-binding phosphoprotein 3.00e-71 C
M041L 41688–41455 78 L? VAC I5L (sp P20500) structural protein (vp13K)? 2.00e-10 S
M042L 42869–41712 386 I VAC I6L (sp P12925) 1.00e-12 C
M043L 44151–42865 429 L VAC I7L (sp P20501) Core protein/morphogenesis
factor
1.00e-73 C
M044R 44157–46190 678 L?, I? VAC I8R (sp P20502) RNA helicase/
nucleophosphohydrolase II
0.00e00 C
M045L 47962–46193 590 I VAC G1L (sp P21022) Putative 68K protein/virion
morphogenesis
0.00e00 C
M046L 48294–47962 111 L VAC G3L (sp P21024) 1.00e-23 S
M047R 48288–48962 225 E VAC G2R (sp P21023) Isatin-b-thiosemicarbazone-
dependent late gene
expression regulator
3.00e-56 S
M048L 49309–48926 128 L VAC G4L (sp P21025) Glutaredoxin 2
homolog/membrane protein
3.00e-27 S
M049R 49312–50604 431 E? VAC G5R (sp P21026) 3.00e-87 S
M050R 50611–50799 63 E VAC G5.5R (gi 335676) RNA polymerase subunit
(rpo7)
1.00e-23 C
M051R 50805–51326 174 ? VAC G6R (sp P21027) 4.00e-36 S
M052L 52350–51301 350 L VAC G7L (sp P21028) Structural protein 3.00e-92 S
M053R 52380–53159 260 I VAC G8R (sp P21029) Late trans-activator protein
VLTF-1
1.00e-26 C
M054R 53183–54178 332 L VAC G9R (sp P21030) Myristylated protein 2.00e-86 S
M055R 54182–54907 242 L VAC L1R (sp P20540) Myristylated virion protein
(IMV)
6.00e-96 C
M056R 54965–55261 99 E VAC L2R (sp P20843) 2.00e-06 S
M057L 56176–55217 320 L VAC L3L (sp P21031) 3.00e-86 C
M058R 56201–56953 251 L VAC L4R (sp P20981) Major core protein (vp25K-
like)/nucleic acid-binding
protein
9.00e-87 C
M059R 56975–57361 129 L VAC L5R (sp P07615) 3.00e-27 S
M060R 57318–57761 148 L CAP F7 (sp P19746)/VAC J1R
(sp P21032)
Virion protein dimer 5e-46/3e-36 C
M061R 57797–58330 178 E VAC J2R (sp P03297) Thymidine kinase 3.00e-65 C
M062R 58406–58879 158 E CAP CF8A (sp P19747)/VAC
C7L (sp P17363)
Host range/virulence factor
(Table 5)
2e-30/7e-13 S
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M063R 58939–59583 215 E CAP CF8A (sp P19747) Host range/DAXX-like motif
(Table 5)
1.00e-14 S
M064R 59631–60239 203 E CAP CF8A (sp P19747)/VAC
C7L (sp P17363)
Host range/virulence factor
(Table 5)
7e-26/7e-11 S
M065R 60284–61297 338 L? VAC J3R (sp P21033) Poly(A) polymerase regulatory
subunit/mRNA
methyltransferase
1.00e-154 C
M066R 61200–61754 185 E? VAC J4R (sp P07391) RNA polymerase subunit
(rpo22)
5.00e-69 C
M067L 62161–61763 133 L? VAC J5L (sp P21083) Essential 9.00e-47 C
M068R 62235–66092 1286 E, (I?) VAC J6R (sp P20504) RNA polymerase subunit
(rpo147)
0.00e00 C
M069L 66614–66081 178 L VAC H1L (sp P20495) Tyrosine/serine phosphatase 7.00e-60 C
M070R 66630–67199 190 L? VAC H2R (sp P20496) 3.00e-72 C
M071L 68179–67208 324 L Lumpy skin disease virus p32
(gi 4884704)/VAC H3L (sp
P20497)
Immunodominant envelope
protein (IMV)
1e-107/2e-62 S
M072L 70570–68183 796 L VAC H4L (sp P07241) RNA polymerase-associated
transcription factor RAP94
0.00e00 C
M073R 70698–71279 194 E VAC H5R (sp P20538) Late trans-activator protein
VLTF-4 virosome component
2.00e-27 S
M074R 71310–72254 315 E, L VAC H6R (sp P08585) DNA topoisomerase I 1.00e-14 C
M075R 72257–72697 147 E? VAC H7R (sp P20539) 2.00e-26 S
M076R 72702–75206 835 E VAC D1R (sp P20979) mRNA capping enzyme, large
subunit
0.00e00 C
M077L 75602–75174 143 E? VAC D2L (sp P21008) Structural protein 3.00e-21 S
M078R 75608–76327 240 E? VAC D3R (sp P21009) Structural protein 3.00e-20 S
M079R 76327–76980 218 E VAC D4R (sp P20536) Uracil-DNA glycosylase 2.00e-94 C
M080R 77017–79374 786 E VAC D5R (sp P21010) Nucleoside triphosphatase 0.00e00 C
M081R 79374–81278 635 L VAC D6R (sp P20634) Early transcription factor
subunit/VETF-1
0.00e00 C
M082R 81314–81802 163 E or I VAC D7R (sp P21034) RNA polymerase subunit
(rpo 18)
1.00e-60 C
M083L 82636–81779 286 E? O. cuniculus carbonic
anhydrase I (gi 164840)
Carbonic anhydrase-like/virion
membrane protein
5.00e-40 S
M084R 82685–83302 206 E VAC D9R (sp P21011) 25K mutT-like protein 1.00e-58 C
M085R 83302–84078 259 L VAC D10R (sp P21012) mutT-like protein/down-
regulator of viral gene
expression
2.00e-54 S
M086L 85980–84085 632 L VAC D11L (sp P20637) Nucleoside triphosphatase
I/DNA helicase
0.00e00 C
M087L 86861–86001 287 L? VAC D12L (sp P20980) mRNA capping enzyme, small
subunit/VITF
e-123 C
M088L 88545–86884 554 E, L? VAC D13L (sp P04321) Rifampicin resistance protein
virion protein (IMV)
0.00e00 C
M089L 89021–88575 149 I VAC A1L (sp P20982) trans-Activator protein (late
gene)/VLTF-2
2.00e-54 C
M090L 89729–89058 224 E, I? VAC A2L (sp P07609) trans-Activator protein (late
gene)/VLTF-3
e-111 C
M091L 89953–89729 75 L VAC A3L fragment (WR) (sp
P07608)
Putative 8.9K protein 2.00e-19 C
M092L 91923–89965 653 L VAC A3L (sp P20643) Major core protein/P4b 0.00e00 C
M093L 92438–91962 159 L MC107L (gi 1492050) Core protein 3.00e-05 U
M094R 92477–92968 164 L VAC A5R (sp P20984) RNA polymerase subunit
(rpo 19)
1.00e-44 C
M095L 94089–92971 373 I VAC A6L (sp P20985) e-119 C
M096L 96252–94120 711 L? VAC A7L (sp P20635) Early transcription factor 82K
subunit/VETF
0.00e00 C
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M097R 96302–97159 286 E VAC A8R (sp P20986) VITF-3 subunit 1.00e-04 C
M098L 97393–97166 76 L VAC A9L (sp P20987) 1.00e-25 C
M099L 100099–97397 901 L VAC A10L (sp P20642) Major core protein precursor/
P4a
0.00e00 C
M100R 100114–101052 313 L VAC A11R (sp P20988) 9.00e-89 C
M101L 101537–101055 161 L VAC A12L (sp P20989) Virion protein 1.00e-32 C
M102L 101776–101573 68 L VAC A13L (sp P20990) Virion membrane protein/p8
(IMV)
1.40e-02 S
M103L 102123–101836 96 L VAC A14L (sp P20991) Structural membrane protein/
p16 (IMV)
2.00e-21 C
M104L 102301–102143 53 L MC119L (gi 1492062) Receptor-like fragment
(Table 4)
5.00e-09 S
M105L 102575–102294 94 L VAC A15L (sp P20992) 1.00e-19 S
M106L 103689–102562 376 L VAC A16L (sp P20993) 35K myristylated protein e-111 C
M107L 104307–103708 200 L VAC A17L (sp P16711) Morphogenesis factor
membrane protein (IMV)
1.00e-32 S
M108R 104322–105755 478 I VAC A18R (sp P20534) DNA helicase/negative
transcriptional regulator
e-161 C
M109L 105960–105742 73 L VAC A19L (sp P20994) 5.00e-17 C
M110L 106302–105964 113 L? VAC A21L (sp P20996) 2.00e-34 C
M111R 106301–107593 431 E VAC A20R (sp P20995) DNA polymerase processivity 3.00e-96 S
M112R 107547–108038 164 E? VAC A22R (sp P20997) 1.00e-54 C
M113R 108069–109223 385 E VAC A23R (sp P20998) Intermediate transcription
factor/VITF-3 subunit
1.00e-124 C
M114R 109252–112716 1155 E VAC A24R (sp P19798) RNA polymerase 132K
subunit/IBT resistance
0.00e00 C
M115L 113289–112726 188 L CAP HM2 (sp P16717)/VAC
A27L (sp P20535)
Fusion protein/EEV formation 1e-25/2e-4 S
M116L 113712–113293 140 L CAP HM3 (sp P16718)/VAC
A28L (sp P21086)
7e-52/5e-36 C
M117L 114626–113721 302 E VAC A29L (sp P21087) RNA polymerase subunit
(rpo 35)
1.00e-101 C
M118L 114825–114598 76 L VAC A30L (sp P21088) 4.00e-11 C
M119L 114993–114844 50 E? no hits U
M120L 115764–115000 255 L? VAC A32L (sp P21055) ATPase 7.00e-85 C
M121R 115849–116376 176 E VAC A33R (sp P21056) EEV glycoprotein/lectin-like
(Table 4)
2.00e-22 S
M122R 116386–116901 172 L VAC A34R (sp P21057) EEV glycoprotein (Table 4) 7.00e-41 S
M123R 116937–117473 179 E VAC A35R precursor (sp
P21058)
3.00e-22 S
M124R 117513–118370 286 E MC144R (gi 1492087) Canavalin precursor-like 2.00e-11 U
M125R 118387–118869 161 E U
M126R 118914–119726 271 E VAC A37R (sp P21060) EEV protein 3.00e-19 S
M127L 121053–119719 445 E MSV235 (gi 4049783) Putative photolyase 1.00e-25 U
M128L 121901–121059 281 E? rat CD47 (gi 2394318)/VAC
A38L (sp P21061)
Integrin-associated protein
(CD47) homolog (Table 4)
3.00e-08/
6.00e-05
U
M129R 121900–122307 136 E? VAC E7R (sp P21048) Myristylated protein 2.80e-01 S
M130R 122377–122742 122 E U
M131R 122812–123300 163 L bovine Cu, Zn superoxide
dismutase (sp P00442)
Superoxide dismutase-like 4.00e-38 S
M132L 123814–123290 175 E U
M133R 123886–125574 563 L VAC DNA ligase A50R (sp
P20492)
DNA ligase 1.00e-167 C
M134R 125694–131693 2000 E MC035R (gi 1491978) Surface glycoprotein 0.00e00 S
M135R 131699–132232 178 E VAC B19R (sp P21077) IL-1/IL-6 receptor-like
(Table 4)
9.00e-08 S
M136R 132368–132904 179 L? VAC A52R (sp P21070) 1.00e-03 U
M137R 132908–133837 310 L VAC A51R (sp P21069) 1.00e-34 S
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M138L 134746–133877 290 E Mouse a-2,3-sialyltransferase
(gi 558532)
a-2,3-Sialyltransferase 1.00e-48 U
M139R 134806–135369 188 E VAC A52R (sp P21070) 9.00e-28 S
M140R 135375–137033 553 E? VAC A55R (sp P21073) Kelch ring canal protein
(nonessential)
4.00e-66 S
M141R 137069–137722 218 E X. laevis NCAM2 (sp P36335)/
human OX-2 (sp P41217)
Immunoglobulin domain/OX-2
homolog (Table 4)
2.00e-06/
3.00e-3
U
M142R 137731–138648 306 E VAC B1R (sp P20505) Ser/Thr protein kinase 2.00e-76 S
M143R 138665–139366 234 L VAR D4R (gi 297187)/CPV D7R
(gi 3096983)/EMV 28K (gi
397980)
Zinc ring finger
protein/apoptosis regulator
(Table 5)
2.00e-21/
2e-21/
5.00e-20
S
M144R 139411–140310 300 E? A. trivirgatus membrane
cofactor (gi 2330890)/VAC
C3L (sp P10998)
Complement control protein
homolog/CD46 homolog
(Table 4)
7.00e-23/
1.00e-17
S
M146R 140335–140658 108 E? VAC N1L (sp P21054) Nonessential virulence factor
(Table 4)
1.20e-01 S
M147R 140700–141563 288 E FPV kinase homolog (gi
2393890)
Ser/Thr protein kinase 1.00e-17 U
M148R 141626–143650 675 E Human ankyrin (gi 4803663)/
VAC B4R (sp P21001)
Ankyrin-like/host range
(Table 5)
2.00e-18/
1.00e-10
S
M149R 143655–145124 490 E VAC B4R (sp P21001) Ankyrin-like/host range
(Table 5)
9.00e-13 U
M150R 145191–146672 494 E VAC C9L (sp P21042) Ankyrin-like/host range
(Table 5)
4.00e-07 U
M151R 146684–147682 333 E Human leukocyte elastase
inhibitor (sp P30740)/VAC WR
SPI-2 (sp P15059)
Serpin/SERP-2 (Table 4) 1.00e-47/
6.00e-42
S
M152R 147688–148485 266 E? Human leupin (gi 2118384) Serpin-like/SERP-3 (Table 4) 9.00e-03 U
M153R 148526–148897 124 E SPV C7L (sp P32225)/murine
herpesvirus 68 IE1 homolog
(gi 2317971)
Herpesvirus IE1-like zinc ring
finger protein
1e-12/2e-9 S
M153.1R 148944–149144 67 E Beet soil-borne mosaic virus
75K (gi 3172384)
9.30e-02 U
M154L 149884–149243 214 E VAC M2L (sp P21092) Nonessential gene 1.00e-55 C
M156R 149998–150303 102 L SPV C8L (sp P32224)/VAC K3L
(sp P20639)
Interferon resistance/eIF2a
homolog (Table 5)
5.00e-06/
3.00e-03
S
a See Fig. 1 for diagramatic representations.
b Stop codon is not included (nucleotide 1 is defined in Materials and Methods).
c Length of each ORF given in amino acids.
d Promoter type: early (E), intermediate (I), or late (L); if no consensus promoter was found immediately upstream of the ORF, a question mark is
shown.
e The most relevant match found for each ORF on BLASTp analysis is indicated; the closest vaccinia virus (strain Copenhagen) homolog is indicated
for some ORFs; accession numbers are provided as references for each match. The vaccinia version is indicated for cases where similarity is high
among multiple poxviruses. SFV genes are not included.
f Putative functions or structures were assigned according to functions of host proteins and/or other poxviruses.
g BLASTp scores are indicated for each match in the relevant column (see Materials and Methods). Only values less than e 2 2 are included for
similarities with nonpoxvirus proteins.
h The final three columns indicate whether an ORF is unique (U) ,20% identical; semiconserved (S) (20–50% identical), or conserved (C) (.50%
identical) with respect to at least one gene within the poxvirus family outside the leporipoxvirus genus (see text for details).
Abbreviations: CAP: capripox virus; EMV: ectromelia virus; FPV: fowlpox virus; MC: Molluscum contagiosum; MPV: monkeypox virus; MSV:
entomopoxvirus, Melanoplus sanguinipes; SPV: swinepox virus; VAC: vaccinia virus (strain Copenhagen, unless otherwise indicated); TNF-R: tumour
necrosis factor receptor; ER: endoplasmic reticulum; IFN: interferon; EGF: epidermal growth factor; MGF: myxoma growth factor; EEV: extracellular
enveloped virus; IMV: intracellular mature virus; PKR: double-stranded RNA-dependent protein kinase; VITF: vaccinia intermediate transcription factor;
VETF: vaccinia early transcription factor; VLTF: vaccinia late transcription factor.
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307MYXOMA VIRUS GENOMIC SEQUENCEous myxoma genes, M062R–M064R, are related to the
accinia host-range gene C7L. These three putative myx-
ma host-range genes have been inserted between
061R and M065R, which corresponds to their adjacent
accinia homologs VAC J2R and VAC J3R. Three C7L-like
ost range genes are also found in SFV (Willer et al.,
999), suggesting they may have arisen via recombina-
ion events in an ancestral Leporipoxvirus virus, resulting
n the triplication of a C7L-like precursor gene (Oguiura
t al., 1993).
Two myxoma ORFs in two different positions in the
yxoma genome reveal similarity to VAC I6L in BLASTp
earches. M042L, which is relatively well conserved with
AC I6L, lies between the myxoma counterparts of VAC
5L and I7L, whereas the much less conserved M130R
ies at the opposite end of the myxoma genome. M130R
s a much smaller ORF than VAC I6L, and most of
he similarity between the two proteins occurs at the
-terminus of M130R. A closer similarity is found be-
ween M130R and the human immunodeficiency virus tat
rotein (not shown). A second duplication is seen with
091L, which resembles VAC A3L, and is inserted di-
ectly downstream of M092L, itself a homolog of VAC A3L
p4b major core protein).
Three sets of myxoma ORFs at first glance appear to
e rearranged with respect to their order in the VAC
enome: M046L/M047L (which correspond to the re-
ersed order of VAC G3L and G2R, respectively), M110L/
111R (which correspond to the reversed order of VAC
21L and A20R, respectively), and M136R/M137R (which
orrespond to the reversed order of VAC A52R and A51R,
espectively). However, inspection of the physical ar-
angements of the vaccinia ORFs reveal that their no-
enclature, which derives from the nucleotide number of
he ATG initiating codon, is sometimes at variance with
he order of the main coding sequences themselves.
hus these myxoma genes are in fact colinear with their
accinia counterparts despite their apparently flipped
umbering.
Finally, M129R may be a translocation (to the opposite
nd of the genome) and subsequent mutation of a VAC
7R-like gene, in a fashion similar to M130R. The overall
equence conservation of M129R with its closest vac-
inia virus cousin, VAC E7R, is rather low. Thus we
onsider it to be a only a semiconserved gene in the
yxoma genome.
enetic differences between myxoma and SFV
The entire genomic sequence of another leporipoxvi-
us, SFV, is presented (Willer et al., 1999) as a companion
rticle to this one. It is immediately obvious that the two
iruses share a great degree of similarity at the genetic
evel, however, there are several noteworthy differences.
lthough a future publication will more fully analyze the
imilarities and differences between myxoma and SFV, ohe information given in Table 2 was compiled to give a
rief outline of those genes that differ significantly be-
ween the two viruses. Only one gene, M000.5L/R in
yxoma virus, is completely absent in SFV. M000.5L/R
aps at the very ends of the myxoma TIRs and is pre-
icted to encode a protein 72 aa in length. Due to the
ack of a significant cellular homolog of known function,
t is difficult to speculate on the possible functions of this
rotein.
Only remnant fragments of six other myxoma genes,
amely M008.1L/R, M135R, M136R, M139R, M150R, and
152R, are observed in the SFV genome. M008.1L/R
SERP-1), a secreted serine protease inhibitor, has a
emonstrated potent anti-inflammatory action, and its
ragmentation is thought to be at least partially respon-
ible for the decreased virulence of SFV in European
abbits (Upton et al., 1990). M152R is also predicted to be
erpin-like because it contains structural elements of the
erpin signature (and is thus designated SERP-3); how-
ver, its function has not yet been elucidated. The frag-
entation in SFV of the M135R gene, whose closest
accinia homolog (B19R) has similarity to the interleu-
in-1b receptor (Smith and Chan, 1991; Spriggs et al.,
992), is another notable difference between SFV and
yxoma. M136R and M139R share some similarity with
AC A52R, but the homology between M136R and VAC
52R is much lower. M150R shares a low identity with
AC C9L but also includes multiple ankyrin repeats,
hich makes it a likely candidate for a host-range gene
Johnson et al., 1993).
Two myxoma genes, M023R and M129R, are found in
runcated form in the SFV genome. M023R does not have
ignificant homology to any viral proteins, and M129R
nly has an extremely low similarity to VAC E7R, which is
myristylated late protein (Martin et al., 1997). M153R is
elated to the N-terminal region of S153R, whereas
153.1R has homology to the C-terminal region. Under
ormal circumstances, this would suggest that the myx-
TABLE 2
Myxoma Genes Distinct from SFV
Myxoma aa SFV
Predicted function
in myxoma
000.5L/R 72 Missing ?
008.1L/R 369 Fragmented SERP-1
023R 61 S23R (35 aa) Late protein
129R 136 S129R (78 aa) Myristylated protein
135R 178 Fragmented IL-1/6-receptor homolog
136R 179 Fragmented VAC A52R-like
139R 188 Fragmented VAC A52R-like
150R 494 Fragmented Ankyrin repeats/host range
152R 265 Fragmented SERP-3
153R 124 S153R (187 aa) Zinc finger
153.1R 67 S153R (187 aa) ?ma version is a truncated gene; however, a promoter-
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308 CAMERON ET AL.ike region appears to exist upstream of the M153.1R, at
he 39 end of the M153R gene. Expression analysis of the
153.1R ORF will determine whether it is a pseudogene
r a bona fide novel ORF distinct from SFV. The differ-
nce in virulence observed between myxoma and SFV
nfections of European rabbits may thus be partly attrib-
ted to the divergence of these viruses, largely at their
ear-right TIR genomic regions. Nevertheless, there is
ufficient variation elsewhere between the two genomes
hat makes the accurate assignment of the “virulence
oci” for myxomatosis difficult based on sequence anal-
sis alone.
ignal sequence predictions
The elucidation of the entire genomic sequence of the
irulent Lausanne strain of myxoma virus has provided a
pectrum of novel ORFs to analyze for potential immu-
T
Myxoma Virus Proteins with Pr
Myxoma ORFs
Predicted
cleavage
site
Predicted no.
of aa after
cleavage Predicted t
001R/L (M-T1) 16–17 244 None
002R/L (M-T2) 16–17 310 None
003.2R/L 20–21 93 None
004R/L (M-T4) 16–17 221 TM type 2 (1
retention m
004.1R/L 37–38 (?) 53? None
007R/L (M-T7) 18–19 244 None
008.1R/L (SERP-1) 15–16 354 TM type 1 (3
010L (MGF) 19–20 66 None
016L 37–38 (?) 40? None
035R 21–22 75 TM type 2 (6
037L 20–21 12 None
041L 24–25 54 TM type 2 (4
046L 20–21 91 None
098L 22–23 54 TM type 1 (4
102L 24–25 44 None
103L 29–30 67 TM type 1 (4
104L 22–23 31 TM type 2 (3
uncleaved
110L 23–24 90 None
116L 25–26 115 None
121R 8 to 9 168 TM type 1 (4
122R 37–38 (?) 135? TM type2 (15
leader seq
125R 18–19 143 None
128L 15–16 266 5 TMs (113–
212–231, 2
134R 16–17 1984 6 TMs (171–
1328–1346
135R 18–19 160 TM type 1 (1
141R 16–17 202 TM type 2 (1
144R 20–21 280 TM type 2 (2
153.1R 14–15 53 None
154L 18–19 196 TM type 1 (5oevasive roles in the in vivo system. As a prelude to this envestigation, we analyzed all 159 ORFs for the presence
f putative signal peptides, glycosylation sites, and
ransmembrane regions (Table 3). From this analysis, 29
RFs were predicted to contain N-terminal signal pep-
ides, and of these, approximately half (15 ORFs) include
ne or more putative transmembrane domains. One cau-
ionary note is the possibility that signal peptides (in
articular, those longer than 30 aa), as well as predicted
ransmembrane regions, can sometimes actually be hy-
rophobic stretches buried in the interior of folded pro-
eins. The other possibility is that a putative signal se-
uence may not be cleaved, as we suspect might be the
ase for M104L (discussed later), thus providing an
-terminal transmembrane spanning domain. Taking
nto account the predicted localization of the ORFs in
able 3, 14 of the ORFs are predicted to be either trans-
embrane (cell surface or virion envelope associated) or
N-Terminal Signal Sequences
mbrane domains
Predicted
N-glycosylation
sites Predicted location
2 Secreted
4 Secreted/intracellular
1 Secreted
)/C-terminal RDEL 1 ER
0 Secreted
2 Secreted
3 Secreted
2 Secreted
1 Secreted
0 Transmembrane
0 Secreted
0 Transmembrane (VP 13K)
1 Secreted
0 Transmembrane
0 Secreted
1 Transmembrane (p16)
possible
sequence?
0 Transmembrane
0 Secreted
1 Secreted
1 Transmembrane (EEV?)
ossible uncleaved 1 Transmembrane (EEV?)
3 Secreted
2–165, 174–191,
)
6 Transmembrane
7–999, 1003–1028,
1537, 1944–1961)
33 Transmembrane
) 1 Transmembrane/secreted
) 8 Transmembrane
) 3 Transmembrane
0 Secreted
1 TransmembraneABLE 3
edicted
ransme
54–175
otif
2–53)
5–83)
9–73)
6–66)
6–65)
2–53):
leader
6–64)
–36): p
uence?
132, 14
42–265
191, 97
, 1517–
62–178
62–178
57–279
8–76)ndoplasmic reticulum localized. One ORF, M008.1
(
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309MYXOMA VIRUS GENOMIC SEQUENCESERP-1), demonstrated at least one discrepancy: M008.1
s predicted by the TMpredict program to contain a sin-
le TM type 1 (from aa 32–53), whereas it is known
xperimentally to be a secreted glycoprotein (Nash et al.,
997).
mmunomodulatory proteins
A number of the strategies used by myxoma virus to
odulate the host immune response have already been
dentified and well characterized (Jackson et al., 1999;
essud-Petit et al., 1998; Nash et al., 1999; Petit et al.,
996). Myxoma virus encodes a number of proteins that
ave been shown experimentally to function as secreted
iroceptors or virokines. For example, M-T1 (M001L/R)
inds and inhibits the activity of CC chemokines, M-T2
M002L/R) is a tumor necrosis factor receptor homolog,
-T7 (M007L/R) is an interferon (IFN)-g receptor ho-
olog, myxoma growth factor (M010L) is an epidermal
rowth factor-like growth factor, and SERP-1 (M008.1L/R)
s a secreted serpin with anti-inflammatory activity (Nash
t al., 1999). Myxoma virus also uses important intracel-
T
Myxoma Proteins with Pote
ORF aa
Calc (obs)
MW (kDa)a Homologs
001R/L 260 28.4 (40) VAC 35-kDa protein B29R S
002R/L 326 35.2 (55–60) Monkeypox TNF-R homolog S
007R/L 263 30 (37) VAC B8R I
008.1R/L 369 41.6 (55) Bovine plasminogen activator
inhibitor 1
S
010L 85 9.6 Rat transforming growth factor-a E
104L 53 6.3 Ateline herpesvirus 3 ORF 74 (gi
4019301)
R
121R 176 19.7 Human NKG2-D (sp P26718) N
122R 172 19.7 Mouse Ly-49C (gi 1330631) N
128L 281 32.1 CD47 (integrin-associated
protein) (gi 2394318)
C
135R 178 20.4 VAC B19R I
141R 218 23.7 Human OX-2 (sp P41217) O
144R 300 34.2 VAC C3L C
146R 108 12.5 VAC N1L V
151R 326 38 VAC SPI-2 S
152R 266 30 Leupin (gi 2118384) Z
a Calculated molecular weights predicted from aa sequence are com
f the fully modified glycoprotein.ular strategies to mediate host range or circumvent (iverse antiviral pathways: for example, M-T2 (M002L/R),
-T4 (M004L/R), M-T5 (M005L/R), M11L (M011L), and
ERP-2 (M151R) serve to inhibit various apoptotic path-
ays that are triggered by viral infection in certain cell
ypes (reviewed in McFadden and Barry, 1998; Turner
nd Moyer, 1998). Myxoma virus has also been shown to
own-regulate CD4 and class I MHC expression in in-
ected cells, but the genes responsible for this have not
et been identified (Barry et al., 1995). We expect that
any more virulence genes, in addition to those contain-
ng obvious predicted immunomodulatory or host-range
omains (Tables 4 and 5), will be uncovered in future
ene disruption studies. In the next few sections, several
andidates for novel immunomodulatory or host-range
roteins listed in Tables 4 and 5 are considered in
reater detail.
141R: Member of the OX-2/NCAM family
One of the myxoma genes encoding a predicted mem-
rane-associated protein, M141R, shares aa homology
ith the Xenopus laevis neural cell adhesion molecule
Immunomodulatory Motifs
posed function/motif aa identity Predicted localization
d chemokine binding
n (M-T1)
94/260 (36%) Extracellular
TNF-R homolog/apoptosis
tor (M-T2)
156/315 (49%) Intracellular and
extracellular
ceptor homolog, a chain
)
49/192 (25%) Extracellular
d anti-inflammatory serpin
-1)
121/363 (33%) Extracellular
growth factor (MGF) 28/83 (28%) Extracellular
r-like fragment 17/40 (42%) Membrane associated
receptor homolog?/EEV
onent C-type lectin
family?
18/52 (34%) Type 2 membrane
receptor homolog?/EEV
onent C-type lectin
in (47–167)
29/127 (22%) Type 2 membrane
e 55/229 (24%) Transmembrane (5-TM)
receptor-like 40/149 (26%) Membrane associated
molog/Ig domain (32–105) 24/85 (28%) Membrane associated
ment binding protein
log/CD46-like 3-CCP
9, 84–144, 149–205)
46/130 (35%) Membrane associated
e factor 28/101 (27%) Cytoplasmic?
SERP-2) 116/346 (33%) Cytoplasmic
er (217–254)/RNA binding
8) (SERP-3)
47/228 (20%) Cytoplasmic
ith observed molecular mass values (when available, in parentheses)ABLE 4
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Pro
ecrete
protei
oluble
regula
FNg re
(M-T7
ecrete
(SERP
GF-like
ecepto
K cell
comp
super
K cell
comp
doma
D47-lik
L-1/IL-6
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310 CAMERON ET AL.ies (Table 4). A potential OX-2 homolog has also been
dentified in human herpes virus 8 (HHV8) (Russo et al.,
996), but information regarding its characterization has
et to be reported. In comparison with the rat, human,
nd HHV8 OX-2 molecules, the myxoma homolog shares
equence identity of 20–22% and sequence similarity of
4–42%. The translated sequence of the M141R gene is
redicted to encode a protein of 218 aa with a molecular
eight of approximately 24 kDa, containing an immuno-
lobulin domain and sites for N-glycosylation. The
T
Predicted Apoptosis Regulators o
ORF aa
calc (obs)
MW (kDa)a Homolog aa identity
004R/L
(M-T4)
237 26.5 (30) CAP T4 82/225 (36%
005R/L
(M-T5)
483 55.5 (55) Human ankyrin 68/266 (26%
011L
(M11L)
166 18.8 (18) SPV C10 41/155 (26%
029L 115 12.8 VAC E3L 45/102 (44%
062R 158 18.4 VAC C7L 47/148 (31%
063R 215 24.6 DAXX (gi 2648018) 27/88 (30%
064R 203 23.8 VAC C7L 35/137 (25%
143R 234 27.9 EMV 28K protein 65/235 (27%
148R 675 77.4 Human ankyrin 161/642 (25%
149R 490 56.7 VAC B4R 90/435 (20%
150R 494 57.8 VAC C9L 91/447 (20%
156R 102 12 VAC K3L 20/60 (33%
a Calculated molecular weights predicted from aa sequence are com
f the fully modified glycoproteins.
FIG. 2. Alignment of N-terminal regions of human OX-2 and M141R. B
Ig) domain in OX-2 and M141R. Arrows denote the two conserved cys
onsensus residues, including those conserved in V-like Ig domains; c
ites in M141R are denoted with circles. Amino acid identities are in shaded141R protein shares features with the cellular OX-2,
ncluding a predicted N-terminal signal sequence and a
-terminal transmembrane domain. The putative myx-
ma OX-2 homolog contains the two highly conserved
ysteine residues involved in the formation of the V-like
mmunoglobulin domain (Fig. 2). In addition, it contains
everal critical residues that are almost invariably con-
erved in immunoglobulin domains: Asp111 and Gly113
ear the C-terminal conserved Cys117 residue and Trp60
ear the N-terminal conserved Cys47 residue. A striking
Range Proteins of Myxoma Virus
Proposed function/motif Predicted localization
-localized apoptosis regulator/RDEL;
helix-loop-helix (127–135)
Endoplasmic reticulum
optosis regulator; 7 ankyrin repeats;
RNAse3 domain (218–292)
Cytoplasmic
ti-apoptotic integral membrane protein/
TM (140–160); helix-loop-helix (82–90)
Membrane associated
R (ds RNA-dependent protein kinase)
inhibitor; IFN resistance/host range
Cytoplasmic
rulence factor/host range Cytoplasmic
omain with similarity to Fas-binding death
associated protein/apoptosis regulator?
?
rulence factor/host range Cytoplasmic
optosis regulator/zinc finger (173–218) Cytoplasmic
TM (215–235, 251–271, 439–459,
477–497); 9 ankyrin repeats
Cytoplasmic ?
Ankyrin repeats Cytoplasmic
Ankyrin repeats Cytoplasmic
F2a homolog; interferon resistance/S1
RNA binding
Cytoplasmic
ith observed molecular mass values (when available, in parentheses)
above the OX-2 residues denotes the V (variable)-like immunoglobulin
that define the Ig domain boundary; asterisks identify Ig superfamily
signify conserved N-linked glycosylation sites in OX-2; and predictedABLE 5
r Host
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311MYXOMA VIRUS GENOMIC SEQUENCEomology exists around the C-terminal conserved
ys117 residue, which is known to be a region of strong
omology in V-like immunoglobulin domains. Recently, it
as shown that expression of murine OX-2 prolongs
enal allograft survival by modulating T cell stimulation
Gorczynski et al., 1999, 1998). We propose that the myx-
ma OX-2 homolog could play a role in the development
f immune tolerance by acting as a costimulator for T-cell
nergy, thus providing an immunoprivileged environment
or myxoma virus infection.
128L: Homolog of CD47
Another myxoma gene that is predicted to encode a
embrane-associated protein with possible immuno-
odulatory function is M128L (Table 4). The best BLASTp
atch was obtained when M128L was compared with
he rat CD47 (integrin associated protein) molecule, and
onsiderably less similarity was demonstrated to the
losest poxvirus homolog, vaccinia A38L (Table 1). Vac-
inia A38L is expressed as an integral membrane glyco-
rotein involved in the influx of extracellular calcium
Parkinson et al., 1995; Sanderson et al., 1996), but its in
ivo function is unknown. M128L is 281 aa residues, with
predicted molecular weight of 32 kDa, including an
-terminal signal sequence, five to six predicted trans-
embrane domains, and a short cytoplasmic tail. Cellu-
ar CD47 is a plasma membrane protein with an extra-
ellular immunoglobulin variable-like domain, five trans-
embrane domains, and a short cytoplasmic tail (Porter
nd Hogg, 1998). Although M128L is not predicted by
onventional programs, such as SMART and Prosite, to
ave a classic immunoglobulin-like domain, there is sig-
ificant conservation of cysteine residues and flanking
a that map to the CD47 immunoglobulin boundary do-
ain (Fig. 3A). Moreover, the two molecules are strik-
ngly similar in the overlapping location of their predicted
embrane-spanning domains (underlined in Fig. 3A), as
redicted by von Heijne transmembrane analyses (Fig.
B). Given the importance of CD47 in the host defense
ystem, as evident in the decreased resistance to bac-
erial infection and the granulocyte defects observed in
D47-deficient mice (Lindberg et al., 1996), we predict
hat M128L is a cell-surface immunomodulator. Recently,
t has been shown that under appropriate conditions,
D47 activation results in the rapid death of T cells via a
ovel apoptotic pathway (Pettersen et al., 1999). Thus
128L protein could act either as a cell surface decoy for
he CD47 ligand that initiates an apoptotic response or
s an intracellular sink for signaling molecules of this
poptotic cascade.
104L: A truncated receptor-like fragment
The myxoma gene M104L is predicted to encode a
mall 53 aa protein with significant aa similarity to anmportant domain of a member of the G protein-coupled ceceptor family (Table 4). In particular, M104L shows
losest similarity to the interleukin-8 receptor-like spe-
ies encoded by the Ateline herpesvirus 3 ORF 74 (Fig.
), a member of the ORF74-family of herpesvirus-en-
oded chemokine receptors (Bais et al., 1998; Rosenkilde
t al., 1999). Chemokine receptors are seven-transmem-
rane domain G protein-coupled receptors that are in-
olved in immune cell activation and trafficking (Locati
nd Murphy, 1999; Premack and Schall, 1996; Strader et
l., 1994). Although M104L has no vaccinia or variola
omologs, it does show significant homology to the
C119L gene of M. contagiosum. Interestingly, MC119L
lso shares similarity to a C. elegans gene that appears
o encode a member of the seven-transmembrane rho-
opsin receptor family.
M104L has a predicted molecular weight of 6.3 kDa
nd shares an aa identity of 42% over a 40-residue region
f alignment with the ORF 74 (Fig. 4). Although M104L
ncludes a predicted signal sequence cleavage site ad-
acent to the N-terminal hydrophobic domain (Table 3), it
s unclear whether this motif (which corresponds to
ransmembrane domain 5 of the ORF 74 protein) repre-
ents a true signal sequence or an N-terminal transmem-
rane region. The fact that the M104L protein sequence
ligns to the fifth and sixth transmembrane domains and
ntervening intracellular loop 3 of the chemokine recep-
or is particularly relevant, as this loop is among the
eceptor domains implicated in chemokine receptor sig-
aling (Berson and Doms, 1998; Murphy, 1994) and the
ixth transmembrane domain has been implicated in
eceptor dimerization that could play a role in signal
ransduction (Hebert and Bouvier, 1998; Rodriguez-Frade
t al., 1999). Thus we speculate that inhibition of chemo-
ine receptor signaling by M104L could potentially occur
y heterodimerization with chemokine receptors to pre-
ent functional dimers or through the sequestration of
ownstream receptor signaling molecules.
121R/M122R: Potential similarities to the
K-receptor superfamily
Two of the predicted secreted/cell surface proteins,
121R and M122R, exhibit homology to members of the
atural killer cell (NKC) receptor family: NKG2 (human)
nd Ly-49 (murine), respectively (Table 4). These partic-
lar members of the NKC receptor family bind to class I
HC on target cells and inhibit NKC-mediated cytotox-
city, which is normally responsible for immune surveil-
ance to eliminate cells with decreased class I MHC
xpression levels (Biron et al., 1999; Lanier, 1998; Lopez-
otet and Bellon, 1999). Many viruses, including myx-
ma, have the ability to down-regulate cell surface
xpression of class I MHC, to escape detection by T
ymphocytes via class I MHC-mediated antigen presen-
ation (Boshkov et al., 1992). Thus specific viral anti-NK
ell mechanisms are presumed to exist, and cell surface
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312 CAMERON ET AL.KC decoy receptors would be a reasonable strategy to
revent NK cell recognition. M121R shares aa sequence
imilarity to the C-type lectin superfamily, with highest
imilarity to the human NKG2-D type II integral mem-
rane protein. The corresponding gene for M121R in
accinia, A33R (Table 1), also shares sequence similarity
ith genes thought to encode C-type lectin superfamily
embers, according to BLASTp analysis. The M121R
ene is predicted to encode a protein of 176 residues in
ength, with a molecular weight of 19.7 kDa, including a
redicted transmembrane domain from residues 46–66.
he NKG2 family members (NKG2-A, C, E, and D/F) are
FIG. 3. Alignment of rat CD47 (integrin-associated protein) with M
mmunoglobulin domain of CD47, and TMs 1–5 identify the five predict
omain formation are indicated by arrows. Amino acid identities are
ransmembrane plots of M128L and rat CD47.ound at the cell surface as part of a disulfide-bonded peterodimer in association with the invariant CD94 mol-
cule (Lanier, 1998; Weis et al., 1998). M122R is predicted
o encode a protein 172 aa in length, with a molecular
eight of 19.7 kDa, including a predicted transmembrane
egment from residues 16–36 and, perhaps most inter-
sting, a C-type lectin domain from aa 47–167. The clos-
st cellular homolog for M122R is the murine Ly-49C
olecule (Fig. 5), which is another C-type lectin super-
amily receptor (Lanier, 1998; Weis et al., 1998). VAC
34R, the vaccinia counterpart of M122R (Table 1), also
hares sequence similarity with rat and mouse NKC
eceptor NKR-P1, according to BLASTp analysis. It is
Panel A) Bold lines denote the following domains: IG specifies the
smembrane domains. The two conserved cysteines involved in the Ig
ded boxes, and similarities are in open boxes. (Panel B) von Heijne128L. (
ed tran
in shaossible that these two myxoma NKC receptor homologs
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313MYXOMA VIRUS GENOMIC SEQUENCEunction as constitutively active NKC receptors inhibiting
ell-mediated cytotoxicity if expressed at the cell surface.
he closest vaccinia homologs to M121R and M122R,
33R, and A34R, respectively, are extracellular envel-
ped virus (EEV) glycoproteins that regulate the release
f EEV particles from virus-infected cells by facilitating
ctin tail assembly on intracellular virions (Blasco et al.,
993; Duncan and Smith, 1992; McIntosh and Smith,
996; Roper et al., 1996, 1998; Ro¨ttger et al., 1999; Sand-
rson et al., 1998). Thus a role for M121R/M122R in
yxoma virus dissemination via EEV particles is also a
istinct, but not mutually exclusive, possibility.
utative novel regulators of host range or apoptosis
Table 5 summarizes the myxoma genes that are pre-
icted to play a role in host-range determinations or the
FIG. 3
FIG. 4. Alignment of Ateline herpesvirus 3 ORF 74 (interluekin-8 re
egions, and Sig? identifies a region in M104L that could act as a cleave
pans the fifth and sixth transmembranes and intervening cytosolic loon open boxes.egulation of apoptosis. Some genes (M-T4, M-T5, and
11L) have already been demonstrated to be required
or myxoma infection of T-lymphocytes by modulating the
poptotic response to myxoma virus infection (McFad-
en and Barry, 1998). Others are related to poxvirus
enes with known roles in host range, such as M062R,
063R and M064R, which are similar to the VAC C7L
ene that is required for vaccinia replication in human
ells (Oguiura et al., 1993; Perkus et al., 1990). In the case
f M143R, the closest poxvirus homolog is the 28-kDa
ING zinc finger protein of ectromelia virus, which is
ssential for growth in murine peritoneal macrophages
Senkevich et al., 1995). Interestingly, the homologous
rotein in SFV perturbs the DNA fragmentation compo-
ent of apoptosis (Brick et al., 1998). At least one novel
yxoma gene is a candidate modulator of a relevant
inued
family member) and M104L. TM denotes predicted transmembrane
al sequence or an uncleaved transmembrane. The region of homology
RF 74. Amino acid identities are in shaded boxes, and similarities areceptor
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314 CAMERON ET AL.poptosis pathway. The M063R protein exhibits similarity
o a glutamate-rich domain of human DAXX, a FAS-bind-
ng death associated protein (Chang et al., 1998, 1999).
AXX and M063R share significant aa identity (30%) and
imilarity (46%) over an 88-aa stretch at the C-terminal
alf of M063R.
005R/L and M148R–M150R: Ankyrin-repeat
amily members
Ankyrin repeats are thought to be involved in intermo-
ecular or intramolecular protein–protein interactions
Lambert et al., 1990). Viruses have taken extensive ad-
antage of this particular motif for protein–protein inter-
ctions. More than 508 ankyrin domains can be mapped
n a total of 99 viral proteins using the standard predictive
rograms (Schultz et al., 1998). A large proportion of viral
roteins containing ankyrin-like repeats are present in
he poxvirus family.
In myxoma virus, there are four ankyrin-containing
roteins: M005R/L, M148R, M149R, and M150R (Table 5).
nterestingly, SFV has counterparts for three of these
yxoma ankyrin proteins but lacks a complete homolog
f M150R (Willer et al., 1999). The deletion of M-T5
M005R/L) from wild-type myxoma virus results in a com-
lete loss of virulence in a susceptible rabbit strain, and
t was shown that this M-T5 knock-out virus caused
poptotic death of in vitro infected rabbit lymphocytes
Mossman et al., 1996). Thus M-T5 (M005R/L) can be
lassified as an ankyrin-containing, host-range-deter-
ining virulence factor of myxoma virus.
The three newest members of the myxoma ankyrin
amily, M148R, M149R, and M150R, are predicted to be
ytoplasmic in terms of cellular localization (Table 5).
148R, the largest of the three with a calculated molec-
lar weight of 77.4 kDa, contains nine putative ankyrin
FIG. 5. Alignment of C-terminal regions of murine Ly-49C and M122
sterisks denote predicted N-glycosylation sites, and arrows identify cepeats. M149R, with a calculated molecular weight of h6.7 kDa, contains eight putative ankyrin repeats, and
150R, at 57.8 kDa, is predicted to have five ankyrin
epeats. M148R is the only one of the four ankyrin-like
yxoma proteins for which transmembrane regions are
redicted.
008.1R/L, M151R, and M152R: SERP-1, -2, and -3
There are three ORFs in the myxoma genome that
ncode proteins with serpin signatures (Table 4).
008.1R/L (SERP-1) has already been characterized ex-
ensively as a secreted serpin with anti-inflammatory
apabilities (Macen et al., 1993; Nash et al., 1999, 1997).
SERP-1 knock-out virus was shown to be less virulent
han the wild-type counterpart (Macen et al., 1993), and
urified SERP-1 protein has been shown to be a potent
nti-inflammatory agent in arterial restenosis (Lucas et
l., 1996). Among the in vitro proteinase targets of
ERP-1 characterized are urokinase plasminogen acti-
ator, tissue-type plasminogen activator, plasmin, and
hrombin, all of which bind SERP-1 with high kinetic rate
onstants (Nash et al., 1998). M151R (SERP-2) is a weak
ntracellular inhibitor of interleukin-1b-converting en-
yme (ICE) and granzyme B (Petit et al., 1996; Turner et
l., 1999). SERP-2 has also been demonstrated to be a
irulence factor: a SERP-2 knock-out virus resulted in
educed mortality rates of infected European rabbits
Messud-Petit et al., 1998).
We have named the M152R protein, the new putative
erpin, “SERP-3” to fit in with the nomenclature shared by
he two other myxoma serpins. SERP-3 is calculated to
e a 30-kDa intracellular protein with 20% identity to a
ellular serpin named leupin or squamous cell carci-
oma antigen 2 (Table 4), although the predicted P1-P19
reactive center of the serpin) of leupin is not conserved
n M152R (not shown). It is predicted that M152R/SERP-3
lines are shown above and below predicted C-type lectin domains.
ed cysteines in C-type lectin domains. Boxes are as in Fig. 2.R. Boldas a zinc finger motif (Table 4) and an RNP-1 signature
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315MYXOMA VIRUS GENOMIC SEQUENCEaa 61–68) that would suggest RNA-binding activity. A
inal intriguing point about SERP-3 is that like M008.1R/L
SERP-1), it is found in fragmented form in the SFV ge-
ome (Willer et al., 1999).
Although caution must be exercised in assigning func-
ions to potentially immunomodulatory domains, previ-
us experience has indicated that even lower similarity
cores can be significant. For example, the myxoma
FN-g receptor homolog (M007L/R) demonstrates only
0% sequence identity to the ligand-binding domain of
he cellular receptor counterparts, yet it binds and inhib-
ts IFN-g with similar affinity to that of the host receptors
Upton et al., 1992).
oncluding Remarks
This myxoma sequence, in conjunction with the con-
urrent publication of the SFV sequence (Willer et al.,
999), provides a comprehensive look at a distinctive
enus of the poxvirus family, the Leporipoxviruses. Myx-
ma virus encodes many of the housekeeping and struc-
ural genes that are conserved among the fully se-
uenced poxviruses and shares certain virulence factors
ossibly as the result of independent gene-capture
vents, such as M-T1 (M001R/L), which is closely related
o the 35-kDa orthopoxvirus family of chemokine-binding
roteins. In general, we predict that the genes that ap-
ear to be most divergent from other sequenced poxvi-
us family members are likely enriched for novel immu-
omodulatory factors. Knowledge gained from studies of
he in vivo effects of immunomodulatory molecules such
s those discussed here will provide a more comprehen-
ive perspective of poxvirus–host immune interactions.
MATERIALS AND METHODS
yxoma virus DNA isolation, cloning, and sequencing
Viral genomic DNA was prepared using the method
utlined elsewhere (Esposito et al., 1981). Briefly, roller
ottles of baby green monkey kidney cells were infected
ith myxoma virus (Lausanne strain, from ATCC), viral
ores were isolated with sucrose cushion centrifugation,
nd viral DNA was extracted with phenol–chloroform.
Random genomic fragments of viral DNA were gener-
ted by sonication at 0°C. The sheared DNA was then
thanol precipitated, and blunt ends were generated
sing both T4 and Klenow polymerases. After phenol–
hloroform extraction and ethanol precipitation, the DNA
as separated on a 0.8% agarose gel and fragments of
.5–3.0 kb were excised and purified. With a 3:1 ratio of
nsert to vector ends, the myxoma DNA fragments were
hen blunt end ligated into the EcoRV site of calf intesti-
al phosphatase-treated pBluescript II (KS1) vector
Stratagene) by incubation at 16°C overnight with T4
NA ligase (GIBCO). The ligation mixture was then trans-ormed into Escherichia coli ElectroMAX DH10B electro- Aompetent cells (GIBCO). Polymerase chain reaction
PCR), using T3 and T7 primers (Promega), was per-
ormed directly on positive colonies to identify clones
ontaining inserts of the appropriate size for sequence
nalysis. Cycle sequencing reactions were performed at
he DNA Sequence Facility at The John P. Robarts Re-
earch Institute, which uses the ABI377 DNA sequencer.
equencing reactions were performed initially with
13F/R primers and subsequently with uniquely tailored
rimers, when additional sequencing information was
equired from a given clone.
The nucleotide sequences obtained from the sheared
ragments of myxoma virus DNA were manipulated using
equencher 3.0 software (GeneCodes Corporation).
ontigs were generated by assembling incoming nucle-
tide sequences automatically, with an 80% minimum
atch of overlapping nucleotide sequences and a 40-bp
inimum overlap used as the contig building parame-
ers. This ensured a random but stringent association of
NA sequence.
At the end of the first phase of sequencing, five large
ontigs of overlapping sequence were generated. To
rient these five sections of the myxoma genome with
espect to one another, the predicted restriction enzyme
rofiles for EcoRI, KpnI, BamHI, SalI, HindIII, BglI, PstI,
nd PvuII were compared with those previously pub-
ished for the myxoma virus Lausanne strain (Russell and
obbins, 1989). In this way, the contigs could be aligned
n the correct order to fit the restriction map of myxoma
ausanne.
A second myxoma DNA library containing larger in-
erts was screened to close the gaps between the five
ajor contigs. Random viral DNA fragments of 5–10 kb
ere generated by partial Sau3A restriction enzyme di-
estion and size selected on a 1% agarose gel. The
urified DNA was ligated into calf intestinal phospha-
ase-treated BamHI digested pMJ601 plasmid vector
Davison and Moss, 1990) and transformed into Electro-
ax DH10B electrocompetent E. coli cells (GIBCO). Dot-
lot hybridizations with probes to DNA sequence at the
dge of each contig were carried out to identify potential
ap region-containing clones. Sequence analysis with
rimers designed to bind and span the gap region was
erformed.
A single gap remained in the assembled contig se-
uence after probing our two libraries, so specifically
esigned internal primers were used to amplify the gap
egion using PCR. Multiple independent reactions were
arried out directly on myxoma DNA, and the resulting
CR products were sent directly for sequence analysis,
ith custom-designed primers. This approach was suc-
essful in obtaining the sequence that bridged the gap
etween the two large remaining contigs.
The terminal nucleotide sequence was obtained by
igating a blunt-ended adapter (29-base upper strand,ATTCTAGAAGCTTCGGATCCCGGGTACC; 25-base
l
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316 CAMERON ET AL.ower strand, GGTACCCGGGATCCGAAGCTTCTAG) to
ung bean-treated myxoma genomic DNA. Subse-
uently, PCR amplification of the terminal sequence was
erformed using specifically designed primers comple-
entary to (1) a region adjacent to the M001L/R gene
nd (2) the upper strand of the adapter sequence. Three
eparate PCR products were sequenced in both direc-
ions. The resulting sequence was found to contain the
onserved terminal resolution sequence that in SFV
aps next to the extrahelical bases at the hairpin termi-
us (Upton et al., 1987).
omputer-based nucleotide and aa analysis
The final edited myxoma virus consensus sequence
as subjected to an ORF analysis in all six possible
eading frames using MacVector 6.0.1 software (Oxford
olecular Ltd.). Using a minimum cut-off of either 50 aa
r, in one instance, 25 aa, each candidate ORF was
ranslated to its primary aa sequence using MacVector.
raditional eukaryotic translational start and stop codons
ere used to delineate the ORFs. The resultant aa se-
uences were analyzed for homologies to other proteins
ontained in public domain databases by unfiltered
LASTp (Altschul et al., 1997). This allowed for the as-
ignment of putative functions to most ORFs. All BLASTp
earches reflect the contents of protein and public nu-
leotide databases as of June 16, 1999.
Further analyses were conducted on the aa sequence
f selected ORFs. Cell sorting predictions were per-
ormed using PSORTII (Horton and Nakai, 1996, 1997),
hich determines the likelihood of the presence of a
ignal peptide in a given ORF and subcellular localiza-
ion of the putative proteins. Upstream nucleotide se-
uences were examined to determine whether early-,
ntermediate-, or late-type promoters may be present.
acVector was used to calculate the molecular weights
nd pIs of selected ORFs and to plot the hydrophilicity of
heir aa sequences using the scale of Kyte and Doolittle
1982). Both ProfileScan (Bucher and Bairoch, 1994; Hof-
ann et al., 1999) and SMART (Schultz et al., 1998) were
sed to search for specific motifs in particular ORFs,
ncluding transmembrane regions, ring finger domains,
nkyrin repeats, and immunoglobulin-like domains.
Certain ORFs with interesting homologies and pre-
icted functions were subjected to both CLUSTALW mul-
iple alignments (with a gap penalty of 10) with the help
f MacVector or the GAP function of GCG (Wisconsin
enetics Computer Group) (gap penalty of 12) to their
ellular or viral counterparts. This allowed for both the
isualization and the calculation of aa identities and
imilarities. The accession number for the entire myx-
ma sequence is AF170726.
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